# 1. Financial Performance ## A. Key Figures * **Revenue (Q4):** **₹2,024.3 Cr** ($222.1M) (+29.1% INR / +22.2% CC) * **Revenue (FY26):** **₹7,192.9 Cr** ($814M) (+29.1% INR / +23.6% CC) * **Adj. EBITDA:** **₹503.6 Cr** Q4 (24.9% Margin) · **₹1,820 Cr** FY26 (25.3% Margin) * **Adj. PAT (FY26):** **₹1,130.6 Cr** ($127.9M) (+39.5%) · 15.7% Margin * **Cash Conversion:** **104.6%** Operating Cash Flow conversion (Q4) ## B. Revenue Growth * **Guidance Outperformance:** Results exceeded projections due to a **$7 million beat** in a single quarter, fueled by a stronger-than-expected open enrollment season and robust execution. * **Organic Momentum:** Sustained double-digit organic growth in constant currency terms highlights strong underlying demand in payer and provider operations, independent of M&A. * **Surge Revenue Contribution:** Seasonal surge revenues outperformed initial expectations, reaching **6%** of total annual revenue. * **Long-term Scalability:** Achieved a consistent three-year revenue CAGR in constant currency, underpinned by the ability to scale while maintaining operational discipline. ## C. Margins & Profitability * **Margin Dynamics:** While full-year EBITDA margins remained healthy, they saw a slight year-on-year contraction primarily due to the integration of the **BroadPath acquisition**. * **Profitability Drivers:** Bottom-line expansion significantly outpaced revenue growth, aided by operational efficiencies, reduced finance costs, and **Forex gains**. * **Capital Efficiency:** The business continues to deliver high returns on capital, with adjusted ROCE consistently exceeding **50%**. * **Earnings Quality:** Adjusted PAT margins expanded by 110 bps, supported by lower interest burdens and favorable timing of wage hikes. ## D. Balance Sheet & Cash Flow * **Working Capital Stability:** Receivables cycles remained largely stable at **87 days** DSO; a minor uptick was attributed to a technical accounting reclassification rather than a shift in liquidity. * **Cash Flow Outlook:** Despite lower year-on-year conversion in FY26 due to higher tax outflows and non-cash adjustments, management maintains a positive outlook on sustaining healthy cash generation. --- # 2. Operating Segments & Mix ## A. Key Figures * **Revenue Mix (Payer/Provider):** **89.7%** Payer · **10.3%** Provider * **Provider Revenue:** **$20M–$21M** Quarterly range * **H1/H2 Revenue Split:** **45% / 55%** (vs. 47% / 53% historically) ## B. Payer & Provider * **Strategic Rebalancing:** The revenue mix has shifted heavily toward the Payer segment following the BroadPath acquisition, though the Provider segment continues to grow on a year-over-year basis. * **Provider Growth Drivers:** Management is pivoting toward larger engagements focused on **significant cost take-out opportunities** and end-to-end Revenue Cycle Management (RCM). * **Domain Expertise:** Competitive positioning is anchored by over **26 years** of specialized U.S. healthcare experience across medical, pharmacy, and dental lines. ## C. Onshore & Offshore * **Onshore Growth Drivers:** Domestic delivery expansion is fueled by regulatory mandates in Medicaid, Payment Integrity services, and the integration of BroadPath. * **Client Adoption Trends:** While existing clients maintain offshore stability, new mid-market clients are increasingly opting for onshore models as an initial entry point before considering global delivery. * **Structural Outlook:** Headcount and revenue ratios are expected to remain consistent with historical trends over the next three years, despite a marginal near-term tilt toward onshore delivery. ## D. Seasonal Revenue * **Pronounced Seasonality:** Seasonal contributions doubled as a percentage of total revenue, driven by the Annual Enrollment Period (AEP) and clinical business surges in the second half of the year. * **Recurring Momentum:** The elevated seasonal component is expected to reoccur in FY27, establishing a new baseline for H2 performance weighting. * **Volume Resilience:** Higher volumes were recorded across all practice areas despite a challenging broader healthcare payer environment. ## E. Geography Mix * **Margin Implications:** A strategic shift toward U.S. onshore operations is impacting weighted average margins, as domestic delivery typically carries lower profitability than offshore alternatives. * **Revenue Recognition Dynamics:** Management noted that geographic mix shifts—specifically moving work to lower-cost geographies—can result in a net reduction of reported top-line revenue despite maintaining volume. * **Growth Velocity:** Onshore geographies are projected to outpace offshore growth rates in the near term, potentially creating continued pressure on consolidated margins. --- # 3. Customer Metrics & Pipeline ## A. Key Figures * **Client Concentration:** **<60%** Revenue from Top 3 clients * **Client Tiering:** **9** Clients >₹2 Cr (vs. 4 in FY23) * **New Client Wins:** **17** FY26 Total · **2** Q4 FY26 * **Annual Contract Value (ACV):** **$130M** Cumulative FY26 · **$30.7M** Q4 FY26 * Sales Pipeline (TCV): ₹570 Mn – ₹575 Mn Active proposals * **Headcount:** **46,860** End of Q4 ## B. Client Concentration & Portfolio Mix * **Diversification Momentum:** Revenue concentration is improving as non-top five accounts outpace the growth of the largest clients, reflecting a healthier portfolio balance. * **Mid-Market Penetration:** Strategic focus on mid and small-market segments yielded double-digit new client additions, specifically targeting regional and "Blue" health plans. * **Account Mining:** Significant upside remains within the existing base, with multiple clients in the **$5M to $20M** range identified as having potential to double in size. ## C. Contract Value Wins & Revenue Realization * **Consistent Deal Flow:** Quarterly ACV wins have stabilized in the **$30M** range, supported by a mix of new logos and expansions across **18** existing clients in the final quarter. * **Realization Dynamics:** Revenue conversion from contract wins is subject to varying ramp cycles; notably, a significant portion of the **$120M-$130M** ACV was already recognized within the current fiscal year. * **Structural Growth Levers:** Increasing deal complexity and a shift toward on-site engagements are expected to provide a natural tailwind to organic growth rates. ## D. Sales Pipeline & Market Strategy * **Complex Deal Momentum:** High demand for managed services and proprietary, non-RFP conversations is driving the pipeline, though these transformational deals involve longer sales cycles. * **Client Engagement:** Recent summit hosting **80+** attendees highlighted AI integration and medical cost pressures as the primary catalysts for upcoming client spend. ## E. Attrition & Headcount * **Cyclical Workforce Adjustments:** Headcount reductions and elevated attrition in Q4 were primarily seasonal, following the conclusion of the open enrollment (OE) period. --- # 4. Technology & Strategic Initiatives ## A. Key Figures * **Cash Position:** **₹903.8 Cr** End of Q4 * **Dividend:** **₹0.10 per share** Recommended final ## B. AI & Innovation * **Tech-Led Transformation:** The Synchrony suite is pivoting the business toward outcome-focused managed service deals, earning leadership recognition from **NelsonHall, Everest Group, and ISG**. * **Strategic Rebranding:** Transitioned to a "healthcare-first, tech and AI-led" partner, focusing on risk stratification and care enablement to drive client productivity. * **Investment Outlook:** Management expects IT and transformation spending to remain elevated through the coming year to support ongoing AI infrastructure scaling. * **Segment Application:** AI efficiencies are being deployed equally across Payer and Provider segments, specifically targeting revenue cycle improvements via **contingency-based pricing** models. ## C. Managed Service Deals * **Shift in Sales Pipeline:** Client conversations are migrating toward larger, transformative deals that encompass both upstream and downstream processes for long-term cost reduction. ## D. Capital Allocation & M&A * **Deployment Priorities:** Substantial liquidity is earmarked for debt repayment, M&A, and AI capability enhancement; dividends remain secondary to these growth obligations. * **Inorganic Strategy:** Actively scouting for targets in the payer and provider segments to acquire mid-market access or specialized domain differentiation. * **Integration Success:** The **BroadPath** acquisition has already bolstered capacity for seasonal member-facing operations during peak enrollment cycles. * **Collaborative Development:** Post-client summit, the company has moved into early-stage pilots for initiatives co-developed with senior client leadership. --- # 5. Operational & Cost Structure ## A. Key Figures * **Adjusted EBITDA Margin:** **24.9%** Q4 FY26 (Includes **1.7%** one-time bonus impact) * **ESOP Pool:** **3.3%** of equity (Performance-based; **2-year** vesting) ## B. Wage & Bonus Strategy * **Fiscal Alignment Payout:** A one-time catch-up bonus was issued in Q4 to bridge the three-month gap created by shifting the wage increment cycle to an April-March basis. * **Incentive Structure:** New ESOP scheme awaiting approval features a **three-year** vesting period, with grants tied to both corporate and individual performance metrics. * **Margin Offsets:** Recent wage increases are being strategically funded by favorable foreign exchange gains, preserving bottom-line integrity. ## C. IT & Transformation * **Strategic Reinvestment:** Increased "Other Expenses" reflect heavy capital allocation toward AI and digital transformation to drive long-term scalability. * **Footprint Rationalization:** Cost spikes include one-time charges for service center consolidation and associated **asset write-offs** in specific geographies. ## D. Efficiency & Automation * **Operational Resilience:** Internal cost efficiencies and technology deployment are successfully neutralizing client price reductions and contractual cost commitments. * **Cycle Standardization:** The transition from a calendar year to a fiscal year (April-March) cycle is now complete, with regular annual increments set to commence in **FY 2027**. --- # 6. Risks & Healthcare Regulatory ## A. Key Figures * **AI-Driven Revenue Compression:** **2%** projected for FY '27 (vs. **1% to 1.5%** historical) * **Medicare Advantage (MA) Rate Increase:** **2.48%** finalized for CY '27 ## B. Revenue Compression & AI Impact * **Accelerating Tech-Driven Headwinds:** Revenue compression is expected to intensify beyond historical levels due to AI and automation initiatives. * **Strategic Market Share Capture:** Management aims to offset technology-led revenue erosion by leading tech-led transformations and taking accountability for client business outcomes. * **Multi-Factor Volatility:** Top-line projections remain sensitive to membership volume adjustments and geographical shifts from high-revenue to lower-revenue regions. * **Medicaid Exposure:** State Medicaid growth is expected to moderate as expansion incentives expire; however, Sagility currently maintains **low exposure** to this segment. ## C. Regulatory & Utilization Trends * **Utilization Driving Demand:** While MA rate increases have improved, elevated medical utilization is pressuring plans, fueling demand for Sagility’s cost-takeout and star-rating services. * **Alignment with CMS Models:** The new **CMS ACCESS Model** for chronic care management aligns with Sagility’s existing tech-enabled strategy for Medicare Advantage plans. * **ACA Subsidy Outlook:** Pending legislation to extend ACA subsidies aims to stabilize premiums; Sagility notes **limited exposure** to the ACA market but views the trend as a catalyst for AI-led cost reduction. * **Governance & Safety:** The technology pillar is focused on clinical safety, explainability, and auditability to ensure AI solutions meet stringent healthcare regulatory standards. ## D. Currency & Macro Factors * **Operational Hedging:** The company relies on **Rupee depreciation** as a strategic lever to mitigate the impact of domestic wage inflation. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth (FY27):** **Low double-digit** Constant Currency (Organic) * **Adjusted EBITDA Margin:** **24% – 25%** Range (Targeting upper end) * **Effective Tax Rate (ETR):** **24% – 25%** Projected for FY26/27 * **Industry Benchmark:** **7% – 8%** Growth rate ## B. Revenue Growth & Momentum * **Conservative Growth Outlook:** Management is maintaining a cautious stance for FY27 compared to the **17% to 18% dollar growth** seen previously, despite currently outperforming industry benchmarks. * **Drivers of Top-line:** Growth is underpinned by contract carryovers and pricing hikes, with **7% to 8%** of the target already factored in from existing trends. * **Deal Pipeline Variability:** Guidance reflects current visibility; however, the timing of large transformational deals remains a variable that could provide future upswings. * **Inorganic Potential:** Current projections are strictly organic; any future M&A activity would provide growth "over and above" the established baseline. ## C. Margin Targets & Operational Strategy * **FX-Dependent Margin Expansion:** Reaching the upper bound of the guided margin range is contingent on the persistence of favorable foreign exchange levels. * **Offshoring Strategy:** Profitability remains tied to a strategy of migrating new business to lower-cost geographies, with guidance subject to revision as the onshore-offshore mix clarifies. * **Seasonality:** Management expects the updated seasonal revenue distribution patterns observed recently to persist as the new annual norm. ## D. Debt Repayment & Liquidity * **Deleveraging Roadmap:** The company is on track to completely extinguish all remaining debt by the end of FY27. * **Balance Sheet Strength:** Debt clearance is supported by a significant increase in cash reserves and internal accruals between FY25 and FY26.